← Deep Dives / August 1, 2026

$LYEL: A Phase 3 CAR T Bet Priced Like a Phase 1

Sector Research: Making the treatment is the hard part →

At the December 2025 American Society of Hematology meeting, Lyell Immunopharma stood up in front of the field’s best oncologists and showed a 93% overall response rate in relapsed, refractory large B cell lymphoma patients. Seventy six percent complete response. Median progression free survival of eighteen months.1 For a cancer where many patients have run out of options, those are not routine numbers.

The stock is now trading at around $13, roughly 70% below the twelve month high of $45.2 The market capitalization as of late July 2026 is approximately $312 million.3 The company holds $261 million in cash and marketable securities as of March 31, 2026, enough to fund operations into Q3 2027.4 Do that arithmetic and you get a stock where the market is effectively paying almost nothing for two pivotal clinical programs, a purpose built manufacturing facility, and a BLA on track for 2027.

My thesis is simple. The street has priced $LYEL as though the clinical data might evaporate and the company will need to raise survival capital. I think that read is wrong on both counts. The data has been consistent and improving across every update, the balance sheet is not in distress, and there are three distinct catalysts inside the next two quarters that the market appears to be discounting entirely.

The curve

CAR T cell therapy sits in early deployment. The first approvals arrived in 2017, commercial rollout has been slow and expensive, and today only a handful of products have reached meaningful revenue scale. The constraint is not the science. It has never been the science. The constraint is manufacturing: cost, speed, failure rate, and the complexity of turning a patient’s own cells into a living drug.

Cell and gene therapy manufacturing is the fastest growing CDMO segment and also the most technically demanding. The complexity of viral vectors, CAR T cells, and in vivo gene therapies creates substantial barriers to entry and gives established manufacturers significant pricing power. That pricing power reflects genuine scarcity. You cannot build the capacity overnight, and you cannot replicate it cheaply.

The global CAR T cell therapy market is estimated at approximately $5.2 billion in 2025 and is projected to reach roughly $6 billion in 2026, expanding toward $27 billion by 2035 at a CAGR of close to 18%. Non Hodgkin lymphoma, the indication where ronde cel is competing, anchors the largest share of that market.5 The relapsed and refractory segment is the one CAR T has most clearly taken over, and the question now is which products push approved competitors aside.

The single binding constraint in this sector is manufacturing reliability. Every approved CAR T product requires collecting a patient’s cells, shipping them to a central facility, manufacturing a personalized product, and shipping it back, all within a window where the patient’s disease is still manageable. Failure rates matter enormously. A product with a 97% manufacturing success rate is a fundamentally different commercial proposition than one at 80%.6 That number decides physician confidence, hospital adoption, and whether a therapy can actually scale.

The second dimension of constraint is safety. Given the global shortage of capacity, CDMOs and therapy developers maintain strong pricing power, and sponsors often accept higher costs in exchange for faster timelines and secure supply chains. But the hospitals administering these therapies are the bottleneck. A profile that allows outpatient administration removes an entire layer of cost and access friction. That is exactly what ronde cel’s safety data now shows.

The inflection point arrives when a new entrant can demonstrate better efficacy, better safety, and comparable or superior manufacturing versus the currently approved standard of care. Lyell is positioned to make that case in H2 2026, with updated PiNACLE trial data, and again in mid-2027 with the pivotal readout. The market has not priced either event.

The company

Lyell Immunopharma was founded in 2018 and went public in June 2021. It is based in South San Francisco. It is a late stage clinical cell therapy company advancing a pipeline of proprietary next generation autologous chimeric antigen receptor (CAR) T cell product candidates for patients with hematologic malignancies and solid tumors. The company has 161 employees.7

The lead product candidate, rondecabtagene autoleucel, or ronde cel, is an autologous dual targeting CD19/CD20 CAR T cell therapy in development for large B cell lymphoma. The dual targeting matters. Existing approved CAR T therapies target CD19 only. When that antigen is lost or downregulated, which happens in a meaningful proportion of patients, current products fail. Ronde cel targets both CD19 and CD20 simultaneously, with what the company calls a “true OR logic gate,” meaning full potency when either antigen is present. That is a structural improvement over the existing standard of care, not just a marginal tweak.

Ronde cel is manufactured with a process that enriches for CD62L positive cells to generate more naïve and central memory CAR T cells with enhanced stemlike features and antitumor activity. The CD62L enrichment step is the detail most analysts skim past. Memory T cell persistence is one of the key drivers of durable response in CAR T therapy, and the manufacturing process itself is what produces it. This is not a formulation change. It is a different kind of product coming out of the process.

Updated data from the ongoing Phase 1/2 clinical trial presented at ASH 2025 showed a best overall response rate of 93% and a complete response rate of 76% in 29 efficacy evaluable patients with relapsed and/or refractory LBCL in the third or later line setting. Median progression free survival was 18 months as of the data cutoff of September 5, 2025. In the second line setting, response rates were 83% overall and 61% complete in a cohort comprised predominantly of patients with primary refractory disease, the hardest to treat subgroup.8

Lyell began dosing patients in February 2026 in a first of its kind Phase 3 trial testing ronde cel, an experimental dual acting cancer cell therapy, directly against an investigator’s choice of approved CAR T treatments for large B cell lymphoma. That is PiNACLE H2H. It is not a single arm trial comparing ronde cel to historical data. It is a head to head randomized Phase 3 against the current standard. The trial is expected to enroll approximately 400 patients, 200 per arm, at sites in the US, Canada, and Australia.

The manufacturing infrastructure is already built. LyFE, Lyell’s internal facility, has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T cell doses per year. This is significant because it means Lyell does not need a CDMO partnership to reach initial commercial scale. The company controls its own supply chain.

The second program, LYL273, targets metastatic colorectal cancer via a GCC antigen. The Phase 1 trial has been amended to enable seamless expansion into a potential pivotal single arm Phase 2 trial pending regulatory alignment, following an update showing gastrointestinal prophylaxis reduced Grade 2 or higher diarrhea and colitis from 55% to 10%. The trial has reported a 50% overall response rate in patients treated under the new prophylaxis regimen. Colorectal cancer is a much larger market than LBCL. The street is not modeling LYL273 at all, which means that program is priced at zero in the current market cap.

The numbers and what the street expects

$LYEL is pre commercial. Revenue for Q1 2026 was $2 thousand.9 That is not a typo. The company’s entire value sits in two pivotal programs and a manufacturing platform, none of which have yet converted to commercial sales. The relevant financial metrics here are cash, burn, and milestones, not income statements.

As of March 31, 2026, Lyell held $90.8 million in cash and cash equivalents and $170.2 million in marketable securities, and management believes existing resources fund operations for at least 12 months. The Q1 2026 net loss was $24.2 million, down sharply from $52.2 million in Q1 2025.10 Research and development expense fell to $36.6 million and general and administrative expense to $9.6 million in the quarter. The burn is real and ongoing, but the trajectory is the right direction.

Dilution deserves a direct answer. Lyell filed a shelf registration on July 13, 2026, registering up to 1,100,000 shares for resale by Innovative Cellular Therapeutics Holdings Limited under a shelf registration. Lyell is not offering any shares itself and will not receive proceeds from sales made by the selling stockholder. The shares were issued to ICT Holdings on July 10, 2026, after achievement of milestones under a November 2025 exclusive license. This is milestone consideration, not a company fundraise. With 23.3 million shares outstanding, 1.1 million shares hitting the market would represent about 4.7% dilution at current levels, and only if ICT sells everything immediately. That is a manageable overhang.

The private placement earlier in 2026 is worth noting. Lyell closed the second $50 million tranche of a $100 million private placement at $25.61 per share in March 2026. The stock now trades at roughly half that price. Whoever took that placement is sitting on a paper loss. That creates a different kind of overhang than the ICT shelf registration, because it means motivated sellers above $25 could emerge.

Eleven Wall Street analysts have provided a twelve month price target for LYEL, with an average of $43.04. The range spans from a low estimate of $12 to a high of $49. The average price target has been revised upward by 9.61% in the past three months. That is unusual for a stock in a sustained downtrend. Revisions are moving the opposite direction from price.

The technical picture is plainly ugly. The stock has a 50-day moving average of $14.50 and a 200-day moving average of $20.07. The twelve month range is $9.28 to $45.00. The stock is below both moving averages, which means mechanically oriented funds and trend following money is not touching it. Volume on down days has been heavier than volume on up days across recent weeks. This is not a clean technical setup. Anyone buying here is buying against the tape, which means you need the fundamental conviction to sit through more pain before the data catalysts can act as the actual turning point.

Management guidance for Q2 2026 results is expected around August 10 to August 12, 2026, depending on the source.11 The street consensus EPS estimate for that quarter is approximately negative $2.37, with revenue essentially nil.12 For FY2026, consensus shows a loss of around negative $8.94 per share with revenue near zero.13 None of these numbers are the catalyst. The quarter itself is a placeholder. What the August print will really do is either confirm or update the H2 2026 data timeline guidance, and that language is the part worth reading closely.

Why it wins

The actual moat here is a combination of manufacturing process and clinical data that is very hard to replicate quickly. The CD62L enrichment step that Lyell uses to generate a more memory rich T cell product requires specific manufacturing know how. Competitors cannot just copy the process description. They have to build and validate it. That takes years.

The RMAT designation from the FDA is the piece the market seems to have forgotten. The FDA granted ronde cel Regenerative Medicine Advanced Therapy designation in both the third and later line and second line settings, as well as Fast Track designation for the treatment of adults with relapsed or refractory large B cell lymphoma. RMAT designation comes with rolling review rights, more frequent FDA interactions, and a faster path to approval. Combined with a BLA expected in 2027, Lyell is set up for a commercial launch before the end of the decade in a market that generated over $4 billion in DLBCL therapeutics revenue in 2025 alone.14

The outpatient safety profile is a commercial differentiator that is genuinely underappreciated. The approved CAR T therapies, axi cel and liso cel, are largely administered in inpatient settings because of cytokine release syndrome risk. Ronde cel demonstrated a manageable safety profile appropriate for outpatient administration across more than 100 patients. Outpatient administration expands the number of treatment sites that can offer the therapy, reduces cost to the health system, and makes adoption by community oncology centers practical in a way it simply is not for the current standard of care.

The manufacturing success rate of 97% deserves a standalone sentence. In the context of personalized cell therapy, where any manufacturing failure means a patient cannot get their treatment and may run out of time, that number is a commercial guarantee. Physicians who have had patients fail to receive therapy due to manufacturing failures remember it. A 97% success rate is a sales conversation, not just a clinical footnote.15

What could go wrong

The most dangerous risk here is that the PiNACLE data update in H2 2026 disappoints. The existing data come from a relatively small number of patients, 29 efficacy evaluable in the 3L+ cohort at the ASH 2025 cutoff. Response rates from small cohorts often contract as sample sizes grow. If the pivotal update shows a meaningful drop in response rate or a shortening of progression free survival, the stock falls hard and the BLA timeline moves.

The head to head trial, PiNACLE H2H, carries its own separate risk. The trial evaluates ronde cel versus investigator’s choice of axi cel or liso cel in the 2L setting, with event free survival as the primary endpoint. Event free survival trials take time to read out. Even if the drug is better, the data arrives slowly. The stock could remain in a downtrend for eighteen months while enrollment proceeds and nobody outside Lyell’s data safety monitoring board knows what the curve looks like.

The balance sheet is workable, not comfortable. Burning roughly $46 million per quarter against $261 million in cash gives you about five to six quarters of runway into Q3 2027. That is enough to reach the mid-2027 pivotal data readout, but barely. If ronde cel requires any additional development spending or if enrollment runs slower than projected, Lyell will likely need to raise capital before the BLA is submitted. Doing so at current prices would be expensive dilution.

Competition is accelerating. The CAR T space now has well funded challengers including allogeneic, or “off the shelf,” approaches that promise to eliminate the manufacturing and vein to vein time problem entirely. If an allogeneic product reaches approval before ronde cel gets its BLA in, the commercial window narrows. Legend Biotech, Allogene, and others are not standing still. The head to head trial could also help a competitor if axi cel or liso cel’s results look better than expected in a structured trial setting.

The investment thesis

At $312 million market cap, the market appears to be valuing ronde cel’s two pivotal programs and the LyFE manufacturing facility at roughly the net cash value of the company. That implies the probability weighted value of the clinical programs themselves is close to zero. I think the market is wrong about that, and specifically wrong about the timing of how value gets recognized.

What has to be true for this to work: the H2 2026 PiNACLE data update holds together, confirming or improving on the 93% response rate at a larger patient count. The August earnings call guides investors toward a specific data presentation window, creating a concentrated attention event. LYL273’s End of Phase 1 FDA meeting, also expected H2 2026, adds a second catalyst that is currently valued at nothing in the cap structure. Neither of these events is in street estimates, because the street is not modeling commercial revenue until 2027 at the earliest. The gap is not between guidance and consensus revenue, it is between the information content of upcoming clinical data and a market that has moved on.

The specific mispricing is in LYL273. A CAR T therapy targeting colorectal cancer, one of the most common and lethal cancers in the world, showing a 50% response rate at early dose levels with a now manageable safety profile, being moved into a seamless Phase 1/2 expansion toward a pivotal trial, is priced at zero. The LBCL program alone would need to succeed to justify the current share price even modestly. LYL273 is a free call option embedded in the cap structure.

This is a name to hold through the H2 2026 PiNACLE data catalyst and the subsequent August earnings call, not to watch from the sidelines. The timeframe is two to three quarters to the first meaningful re rating event. The longer thesis plays out over 12 to 18 months, into the mid-2027 pivotal readout and BLA submission.

The falsification is clean: if the H2 2026 PiNACLE data update shows a meaningful contraction in overall response rate or complete response rate versus the ASH 2025 data, the thesis is wrong and the stock should be abandoned.

What I am watching

The Q2 2026 earnings report, expected around August 10 to 12, 2026, is not a financial event worth modeling. What I am reading closely is management’s language around the PiNACLE data update timeline. If they give a more specific window than “H2 2026,” that is new information. If they narrow it to Q3 versus Q4, the market will start pricing the event. The earnings report is expected around August 10, 2026, which gives nine days from today.

The End of Phase 1 FDA meeting for LYL273 and additional Phase 1 clinical data, including clinical outcomes, are also expected in the second half of 2026. That meeting is the gate through which LYL273 either advances toward a pivotal trial or encounters a regulatory conversation that slows it down. The outcome changes the valuation of that program from zero to something real, or confirms it stays at zero for longer. Either way it is information the market does not currently have.

I am watching the ICT Holdings resale activity carefully. Lyell registered 1.1 million shares for ICT Holdings to resell. If those shares start trading with visible block volume at the current depressed price, it creates mechanical selling pressure with no fundamental content. Separating that noise from genuine sentiment deterioration matters. Any sustained uptick in daily volume without a price response is worth investigating.

The PiNACLE H2H enrollment pace is worth tracking in quarterly disclosures. The trial targets approximately 400 patients at sites in the US, Canada, and Australia. Enrollment speed drives readout timing, which drives the BLA timeline, which drives everything downstream. Faster enrollment means an earlier commercial shot. Slower means extended cash burn and more dilution risk before the payoff.

The bottom line

CAR T cell therapy is in early deployment on the adoption curve. The constraint that decides when this sector inflects commercially is manufacturing reliability and safety profile, not efficacy data. The efficacy data from ronde cel at ASH 2025 was already the best in its class. What makes Lyell specifically interesting in mid-2026 is that both the manufacturing constraint and the safety constraint appear to have been solved: 97% manufacturing success rate and an outpatient compatible safety profile, confirmed across more than 100 patients.

The stock is in a sustained downtrend, trading well below both its 50-day and 200-day moving averages, with institutional money that bought the March 2026 private placement at $25.61 now sitting deep underwater. That creates the setup, because it also means the next substantial good news event hits a tape that is short side crowded and under owned from the long side. The August earnings call and the H2 2026 PiNACLE data update are not priced. One of them is nine days away.

Not financial advice.

The setup

Lyell Immunosciences is trading at 12.94, sitting 7.0% below its 50 day average and 37.3% below its 200 day average, with the 50 below the 200. That is a confirmed downtrend by any reasonable measure. The stock is at 8% of its 52 week range, meaning it is near the bottom of the past year of price action, and 66.5% off its 52 week high. The 14 day RSI is at 38, not yet at a classic oversold extreme. Volume over the past 10 days is running at 0.77 times the 50 day average, so there is no sign of panic selling or accumulation on elevated volume. Against the market, the 3 month relative underperformance is 41.6 points, which is severe. The trend is clearly against a long thesis right now.

The historical base rate, drawn from 241 prior days when this stock sat in a comparable technical position, shows a median 1 month move of -3.1% and a median 3 month move of -13.9%. The stock was higher a month later 46% of the time and a quarter later only 42% of the time. The quarterly range of outcomes ran from -55.2% to +107.3%, which reflects how wide the distribution of results can be. The sample of 241 days is reasonably large for a single ticker, so the base rate is not thin, but it is still one stock and one ticker’s history. It describes what happened before under similar conditions. It does not tell you what happens next.

References

  1. Lyell Immunopharma, Inc. Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde Cel Showing High Rates of Durable Complete Responses in Patients with Large B Cell Lymphoma at the 67th ASH Annual Meeting and Exposition. GlobeNewswire. Published December 7, 2025. Accessed August 1, 2026. https://www.globenewswire.com/news-release/2025/12/07/3201148/0/en/Lyell-Immunopharma-Presents-New-Clinical-Data-from-Ongoing-Trial-of-Ronde-Cel-Showing-High-Rates-of-Durable-Complete-Responses-in-Patients-with-Large-B-cell-Lymphoma-at-the-67th-AS.html
  2. Investing.com. Lyell Immunopharma Inc Stock Price Today | NASDAQ: LYEL Live. Accessed August 1, 2026. https://www.investing.com/equities/lyell-immunopharma
  3. PitchBook. Lyell Immunopharma 2026 Company Profile: Stock Performance and Earnings. Accessed August 1, 2026. https://pitchbook.com/profiles/company/265477-24
  4. Lyell Immunopharma, Inc. Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026. GlobeNewswire. Published May 6, 2026. Accessed August 1, 2026. https://www.globenewswire.com/news-release/2026/05/06/3289331/0/en/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026.html
  5. Precedence Research. CAR T Cell Therapy Market Size to Hit USD 26,982.3 Million by 2035. Accessed August 1, 2026. https://www.precedenceresearch.com/car-t-cell-therapy-market
  6. Lyell Immunopharma, Inc. Lyell Immunopharma Announces Initiation of Patient Dosing in First of Its Kind Phase 3 Head To Head CAR T Cell Clinical Trial in Aggressive Large B Cell Lymphoma. Published February 12, 2026. Accessed August 1, 2026. https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-announces-initiation-patient-dosing-first-its
  7. Google Finance. Lyell Immunopharma Inc (LYEL) Stock Price and News. Accessed August 1, 2026. https://www.google.com/finance/beta/quote/LYEL:NASDAQ
  8. Lyell Immunopharma, Inc. Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results. Published March 12, 2026. Accessed August 1, 2026. https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-reports-q4-and-full-year-2025-business-and
  9. Lyell Immunopharma, Inc. Form 10-Q for the quarterly period ended March 31, 2026. US Securities and Exchange Commission. Published May 6, 2026. Accessed August 1, 2026. https://www.stocktitan.net/sec-filings/LYEL/10-q-lyell-immunopharma-inc-quarterly-earnings-report-6f89f65cf222.html
  10. Lyell Immunopharma, Inc. Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026. GlobeNewswire. Published May 6, 2026. Accessed August 1, 2026. https://www.globenewswire.com/news-release/2026/05/06/3289331/0/en/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026.html
  11. ChartMill. LYEL Forecast, Price Target and Analyst Ratings | Lyell Immunopharma Inc (NASDAQ:LYEL). Accessed August 1, 2026. https://www.chartmill.com/stock/quote/LYEL/analyst-ratings
  12. ChartMill. LYEL Forecast, Price Target and Analyst Ratings | Lyell Immunopharma Inc (NASDAQ:LYEL). Accessed August 1, 2026. https://www.chartmill.com/stock/quote/LYEL/analyst-ratings
  13. Seeking Alpha. LYEL Lyell Immunopharma Inc Earnings Estimates. Accessed August 1, 2026. https://seekingalpha.com/symbol/LYEL/earnings/estimates
  14. IMARC Group. Diffuse Large B cell Lymphoma (DLBCL) Market Size to Reach USD 5,590.1 Million by 2036. Accessed August 1, 2026. https://www.imarcgroup.com/diffuse-large-b-cell-lymphoma-market-outlook
  15. Lyell Immunopharma, Inc. Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion. GlobeNewswire. Published June 8, 2026. Accessed August 1, 2026. https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/Lyell-Immunopharma-Provides-Update-on-Safety-Profile-of-LYL273-in-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer-and-Amends-Phase-1-Trial-to-Phase-1-2-Expansion.html
  16. DefenseWorld. Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts. Published July 22, 2026. Accessed August 1, 2026. https://www.defenseworld.net/2026/07/22/lyell-immunopharma-inc-nasdaqlyel-receives-43-00-consensus-price-target-from-analysts.html
  17. StockTitan. Lyell Immunopharma registers 1.1M shares for ICT resale. LYEL S-3 Registration. Published July 13, 2026. Accessed August 1, 2026. https://www.stocktitan.net/sec-filings/LYEL/s-3-lyell-immunopharma-inc-shelf-registration-statement-9cc7cc331b97.html
  18. Visionlifesciences.com. CDMO Market Analysis 2026: Size, Trends and Key Players. Accessed August 1, 2026. https://visionlifesciences.com/insights/cdmo-market-analysis
  19. Lyell Immunopharma, Inc. Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde Cel) in Patients with Large B Cell Lymphoma at European Hematology Association 2026 Congress. GlobeNewswire. Published June 12, 2026. Accessed August 1, 2026. https://www.globenewswire.com/news-release/2026/06/12/3311241/0/en/Lyell-Immunopharma-Presents-Updated-Safety-Data-and-Translational-Insights-for-Rondecabtagene-Autoleucel-Ronde-Cel-in-Patients-with-Large-B-Cell-Lymphoma-at-European-Hematology-Ass.html
Positions and business relationships. Assume that Dr. Paul Christianson and/or Disruptor Investing, LLC may hold a long or short position in any security mentioned above, whether or not a position is stated, and may buy or sell at any time without notice. Assume also that a company mentioned above may be a current or former paid client of Disruptor Investing's CEO interview program, or may otherwise have a business relationship with Disruptor Investing. This research is reviewed before publication but is not a substitute for your own diligence. Verify every figure against the company's SEC filings before relying on it. Nothing here is investment, legal, tax, or financial advice. Dr. Christianson is not a registered financial advisor, investment adviser, or broker-dealer. Educational content only. Full disclosures and compensation terms.
See the membership More Deep Dives